BIO Asia–Taiwan 2023 亞洲生技大會

BIO Asia–Taiwan 2023 亞洲生技大會

講師

藥祇生醫股份有限公司

 

Company Info

Name /Pharmasaga Co. Ltd.

Address /C311, No. 99, Lane 130, Sec. 1, Academia Road, Nankang, Taipei, 115, Taiwan

Website /www.pharmasaga.com

Presenter

Name /Jeff Pan

Title /CEO

Email /ceo@pharmasaga.com

Telephone /+886-2-7750-5563

Fax /+886-2-2782-2245

Mobile /+886-937008797

Company Type

Biotechnology,Pharmaceutical

About the Company

Pharmasaga is a spin-off of the Academia Sinica, Taiwan, and was founded in January 2021. The core technology of Pharmasaga is the development of first-in-class drugs for diabetes. Current pipeline products include PS-001 for type 2 diabetes (T2D) and PS-002 for type 1 diabetes (T1D). Both small-molecule drugs can treat and reverse T2D and T1D. Furthermore, the IND of PS-001 was approved by US FDA, and its phase 1 clinical trial was scheduled to launch in September 2022, followed by phase 2 clinical trial starting in 2024.

Brief Description of main products or services

Prevention of β-cell failure holds the key to curing T1D and T2D. Pdia4, a chaperone primarily expressing in β-cells, negatively regulates β-cell failure and diabetes. Accordingly, Pdia4 inhibition can treat and reverse diabetes. Both lines of evidence suggest Pdia4 as a therapeutic target of diabetes. Using molecular docking and total synthesis of compounds, we have finally developed several Pdia4 inhibitors as drug candidates, i.e., PS-001 and PS-002. PS-001 is a first-in-class drug for diabetes. Its mechanism includes inhibition of β-cell pathogenesis and diabetes involving reduction of ROS. Strikingly, 16-week treatment with PS-001 alone or combined with metformin can reverse T2D in mice by 70% and 100%, respectively.

By Feburary 2022, US FDA approved the IND of PS-001 for phase 1 clinical trial. This trial was scheduled to launch in September 2022. Its phase 2 clinical trial will be completed in 2025. Due to the clinical potential of PS-001 for T2D, we believe it will be a blockbuster after NDA, and will shift a paradigm in diabetes treatment and industries.

Besides, PS-002 also has potential to treat and reverse T1D, fallen into a category of orphan diseases.

Any investors and pharmaceutical companies that are interested in diabetes reversal are highly welcome.

Contact Person

Name /Tab Chen

Email /zong770115@gmail.com

Phone /+886-937457634